biostudies-literatureKang EYAlberta Precision LaboratoriesCancer Research UKNCATS NIH HHSNCRR NIH HHSMedical Research CouncilNational Cancer InstituteNCI NIH HHS697-713https://www.ebi.ac.uk/biostudies/studies/S-EPMC10107112biostudies-literatureUnknown129(5)<h4>Background</h4>Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.<h4>Methods</h4>Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.<h4>Results</h4>High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% oCancerCCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.PMC10107112R21 CA210210R01 CA243511R01CA172404U01 CA243483UL1 TR000124RS17‐601, RS10‐526P30 CA008748K07 CA08066822905R01 CA243483R01 CA160669P30 CA071789N01 CA015083P30 CA014089P30 CA047904R01 CA172404R01 CA122443R01 CA248288P50 CA136393P30 CA01508315601M01 RR000056R01 CA095023MC_UU_00004/01Heitz FShah MKobel MHarnett PRBoros JLubinski JHogdall CKCohen PAOlbrecht SMohan GRGronwald JBrucker SYvan-Wagensveld LAlsop JGentry-Maharaj AKhabele DEl-Bahrawy MAShvetsov YBJones MESalfinger SGCourtney-Brooks MCrowe PRodriguez-Antona CStaebler ABerger JToloczko AVan Gorp TOrsulic SLester JRyan APalacios JFischer AJewell ABolithon AModugno FNeuhausen SLHeikaus SMadan RJimenez-Linan MHein APearce CLPopovic GKarlan BYHeublein SGayther SAMeagher NSVierkant RATalhouk ATang KBenitez JConrads TPHorlings HMSundfeldt KHendley JVan Nieuwenhuysen ELoverix LHuntsman DGSchildkraut JMCandido Dos Reis FJCoulson PRiggan MJGarcia MJHuzarski TOlawaiye AGoodman MTWilkens LRBosmuller HLambrechts DHogdall Evan der Aa MABowtell DDLee CHStewart CJRWu AHGrube MTaylor SEFarrington KCybulski CErber RTraficante NKennedy CJWang CBisinotto CLinder APharoah PDPKruitwagen RFPMMillstein JPike MCHarter PSwerdlow AJWinham SJSingh NLambie NKaufmann SHBarlow EQuinn CMSinn HPSchoemaker MJSharma RFereday SMaxwell GLSteele LFasching PAAtaseven BTan ANelson GSSasamoto NCarney MEHecht JLVan de Vijver KKHernandez BYKommoss FKFBrooks-Wilson ABerchuck ALeung BLe NDFarrell RCook LSTerry KLDarcy KMAOCS GroupWeir AHirasawa AGhatage PMenon UPolo SHBrand AHKommoss SBeckmann MWHarrington SPRamus SJCunningham JMSonke GSDeFazio ACramer DWCazorla-Jimenez AGilks CBHartmann AVergote IRuebner MBrenton JDElishaev ECasablanca YKang EYAnglesio MSLeung YLener MGoode ELfalseCCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.<h4>Background</h4>Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC.<h4>Methods</h4>Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated.<h4>Results</h4>High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% o2023-01-01T00:00:00Z2023 Mar2026-03-31T11:52:13.207Z2025-04-06T18:37:32.711ZS-EPMC101071123657299110.1002/cncr.34582